13-Jan-2025 6:00 AM CST - Business Wire CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results CareDx, Inc. (Nasdaq: CDNA) The Transplant Company today reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2024. Preliminary Fourth Quarter 2024 Financial Results Revenue is expected to be between $85 million and $86 million, an increase of approximately 30% year-over-year. Testing services revenue is expected to be between $62.5 million and $63.5 million, an increase of approximately 35% year-over-y
18-Dec-2024 6:05 AM CST - Business Wire CareDx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced that the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. CareDxs management is scheduled to present on Tuesday, January 14, 2025, at
12-Nov-2024 6:05 AM CST - Business Wire CareDx to Participate in Upcoming Investor Conferences CareDx, Inc. (Nasdaq: CDNA) The Transplant Company a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced the company will participate in the following investor conferences. Jefferies London Healthcare Conference 2024 in London, UK. Presentation on Tuesday, November 19 at 9:00 AM GMT/4:00 AM EST
4-Nov-2024 3:05 PM CST - Business Wire CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance CareDx, Inc. (Nasdaq: CDNA) today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Total revenue of $82.9 million increased 23% year-over-year Testing Services volume of 44,600 tests increased 16% year-over-year GAAP net loss of $7.4 million, non-GAAP net income of $8.0 million, and positive adjusted EBITDA of $6.9 million, a significant improvement from the third quarter 2023 Cash flow from
15-Oct-2024 5:00 AM CST - Business Wire CareDx Reports Preliminary Financial Results for Third Quarter 2024 CareDx, Inc. (Nasdaq: CDNA) The Transplant Company a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today reported preliminary financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Third quarter revenue is expected to be in the range of $82 million to $83 million, a
8-Oct-2024 3:05 PM CST - Business Wire CareDx to Host Investor Day on October 15, 2024 CareDx, Inc. (Nasdaq: CDNA) The Transplant Company a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced the Company will be hosting an Investor Day on October 15, 2024, in New York City, New York, starting at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time. The event will feature presentations
13-Jan-2025 6:00 AM CST - Business Wire CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results CareDx, Inc. (Nasdaq: CDNA) The Transplant Company today reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2024. Preliminary Fourth Quarter 2024 Financial Results Revenue is expected to be between $85 million and $86 million, an increase of approximately 30% year-over-year. Testing services revenue is expected to be between $62.5 million and $63.5 million, an increase of approximately 35% year-over-y
18-Dec-2024 6:05 AM CST - Business Wire CareDx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced that the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. CareDxs management is scheduled to present on Tuesday, January 14, 2025, at
12-Nov-2024 6:05 AM CST - Business Wire CareDx to Participate in Upcoming Investor Conferences CareDx, Inc. (Nasdaq: CDNA) The Transplant Company a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced the company will participate in the following investor conferences. Jefferies London Healthcare Conference 2024 in London, UK. Presentation on Tuesday, November 19 at 9:00 AM GMT/4:00 AM EST
4-Nov-2024 3:05 PM CST - Business Wire CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance CareDx, Inc. (Nasdaq: CDNA) today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Total revenue of $82.9 million increased 23% year-over-year Testing Services volume of 44,600 tests increased 16% year-over-year GAAP net loss of $7.4 million, non-GAAP net income of $8.0 million, and positive adjusted EBITDA of $6.9 million, a significant improvement from the third quarter 2023 Cash flow from
15-Oct-2024 5:00 AM CST - Business Wire CareDx Reports Preliminary Financial Results for Third Quarter 2024 CareDx, Inc. (Nasdaq: CDNA) The Transplant Company a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today reported preliminary financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Third quarter revenue is expected to be in the range of $82 million to $83 million, a
8-Oct-2024 3:05 PM CST - Business Wire CareDx to Host Investor Day on October 15, 2024 CareDx, Inc. (Nasdaq: CDNA) The Transplant Company a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced the Company will be hosting an Investor Day on October 15, 2024, in New York City, New York, starting at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time. The event will feature presentations